CombinatoRx and Cystic Fibrosis Foundation Therapeutics Enter into a Collaboration
Development of Novel Therapeutics Built from Synergistic Drug Combinations
CombinatoRx, Incorporated and cystic fibrosis Foundation Therapeutics (CFFT) entered into a collaboration to discover and develop novel therapeutics built from synergistic drug combinations to treat cystic fibrosis (CF). Under the terms of the agreement, CFFT will award CombinatoRx up to $13.8 million in research expenses and will also fund up to 75% of clinical development expenses through Phase 2a on the first potential product candidate, provided both parties agree to commence clinical development. In addition, CombinatoRx will retain full worldwide commercialization rights, receive payments upon successful completion of certain clinical and regulatory milestones, and own new intellectual property generated during the collaboration. CFFT will be eligible to receive royalties from CombinatoRx on net sales of any approved products.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.